Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Genome edited B cells: a new frontier in immune cell therapies

Molecular Therapy(2021)10.1016/j.ymthe.2021.09.019Source: DataRank Database

Genome edited B cells: a new frontier in immune cell therapies is a research paper published in Molecular Therapy (2021). On theSindex it has a DataRank of 0. It has been cited 22 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access22 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.38)OA: greenTopics (68)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Paula M. Cannon ORCID,Geoffrey L. Rogers ORCID

Live enrichment

PubMed:34563675 PMC:PMC8571172 OpenAlex:https://openalex.org/W3204268210

National Institutes of Health

Grant: HL129902

National Institutes of Health

Grant: HL156247

NHLBI NIH HHS

Grant: U19 HL156247

NHLBI NIH HHS

Grant: U19 HL129902

National Institutes of Health

Grant: 1U19HL156247-01

Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure

FWCI

1.38

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: CC BY NC ND

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8571172

publisherhttps://api.elsevier.com/content/article/PII:S1525001621004743?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001621004743?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ymthe.2021.09.019

Fields of Study

CAR-T cell therapy researchCRISPR and Genetic EngineeringViral Infectious Diseases and Gene Expression in Insects0301 basic medicine0303 health sciences03 medical and health sciencesAnimalsAntibodiesB-LymphocytesCRISPR-Cas SystemsCell EngineeringCell- and Tissue-Based TherapyCellular ReprogrammingGene EditingGene Expression RegulationGenetic EngineeringGenetic TherapyHumansImmunotherapyT-Lymphocyte Subsets

MeSH Terms

Gene EditingAnimalsAntibodiesB-LymphocytesGene Expression RegulationGenetic EngineeringHumansImmunotherapyGenetic TherapyT-Lymphocyte SubsetsCell EngineeringCRISPR-Cas SystemsCell- and Tissue-Based TherapyCellular Reprogramming

Keywords

ReprogrammingChimeric antigen receptorBiologyImmune systemGenome editingAntigenAntibodyB cellCell therapyCell biologyCellT cellImmunologyStem cellGenomeGeneticsGeneHIVImmunotherapyB cellsCas9Gene EditingB-LymphocytesCell- and Tissue-Based TherapyGenetic TherapyCellular ReprogrammingAntibodiesGene Expression RegulationT-Lymphocyte SubsetsAnimalsHumansCRISPR-Cas SystemsGenetic EngineeringCell Engineering

Sustainable Development Goals

SDG 3: 3. Good health